Table 3 |
||||
|
Prevalence of HBsAg and HCV by country. |
||||
|
TTI prevalence |
||||
|
|
||||
|
Country |
Reference |
Year |
HBsAg |
Anti HCv |
|
|
||||
|
Botswana |
[2] |
2004 |
0.05 |
NA |
|
South Africa |
[2] |
2004 |
0.05 |
NA |
|
Kenya |
[2] |
2004 |
0.042 |
NA |
|
[39] |
1999 |
0.039 |
0.018 |
|
|
Tanzania |
[40] |
2006 |
0.048 |
NA |
|
[41] |
2006 |
0.088 |
0.015 |
|
|
[42] |
2007 |
0.053 |
0.055 |
|
|
|
||||
|
NA: not available |
||||
|
Guerriero et al. Cost Effectiveness and Resource Allocation 2010 8:1 doi:10.1186/1478-7547-8-1 |
||||
